Canaccord Genuity Reaffirms Their Buy Rating on ChemoCentryx (CCXI)


Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on ChemoCentryx (NASDAQ: CCXI) today and set a price target of $18. The company’s shares opened today at $11.89.

Gilson has an average return of 1.4% when recommending ChemoCentryx.

According to TipRanks.com, Gilson is ranked #568 out of 4850 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ChemoCentryx with a $18.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.08 and a one-year low of $5.42. Currently, ChemoCentryx has an average volume of 284.6K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts